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Renal hypouricemia is an inherited disorder characterized by impaired renal urate (uric acid) reabsorption and subsequent low serum
urate levels, with severe complications such as exercise-induced acute renal failure and nephrolithiasis. We previously identiﬁed
SLC22A12, also known asURAT1, as a causative gene of renal hypouricemia. However, hypouricemic patients withoutURAT1mutations,
as well as genome-wide association studies between urate and SLC2A9 (also calledGLUT9), imply thatGLUT9 could be another causative
gene of renal hypouricemia. With a large human database, we identiﬁed two loss-of-function heterozygous mutations in GLUT9, which
occur in the highly conserved ‘‘sugar transport proteins signatures 1/2.’’ Bothmutations result in loss of positive charges, one of which is
reported to be an important membrane topology determinant. The oocyte expression study revealed that both GLUT9 isoforms showed
high urate transport activities, whereas the mutated GLUT9 isoforms markedly reduced them. Our ﬁndings, together with previous re-
ports on GLUT9 localization, suggest that these GLUT9 mutations cause renal hypouricemia by their decreased urate reabsorption on
both sides of the renal proximal tubules. These ﬁndings also enable us to propose a physiological model of the renal urate reabsorption
in which GLUT9 regulates serum urate levels in humans and can be a promising therapeutic target for gout and related cardiovascular
diseases.Renal hypouricemia (MIM 220150) is a common inherited
disorder characterized by impaired renal urate reabsorption
and subsequent low serum urate levels. Typically, it is asso-
ciated with severe complications such as exercise-induced
acute renal failure and nephrolithiasis.1,2 We previously
reported that the causative gene for renal hypouricemia is
URAT1, also knownas SLC22A12 (MIM607096).3However,
the fact of renal hypouricemic patientswhohavenoURAT1
mutations4,5 implies the existence of another important
urate transporter in the human kidney. Recent genome-
wide association studies have revealed that the most
signiﬁcant single-nucleotide polymorphisms (SNPs) associ-
ated with urate concentrations map within GLUT9 (also
known as SLC2A9 [MIM 606142]), which encodes glucose
transporter 9 (GLUT9) protein.6–9 Yet, neither the physio-
logical role of GLUT9 in vivo nor human cases with func-
tional GLUT9 deﬁciency has been reported previously.
Generally, serum urate levels in humans are higher than
those in most other mammals (such as mice), because
humans lack the urate-degrading enzymehepatic uricase.10
Therefore, to investigate the physiological importance
in human urate regulation by GLUT9, it is of no use to
simply employ GLUT9 gene-targeted mice, because they
express active uricase. Accordingly, we decided to use an
actual human health examination database to genetically
identify and investigate human patients with GLUT9
deﬁciency.744 The American Journal of Human Genetics 83, 744–751, DecembFirst, the health examination database of the personnel
of Japan Maritime Self-Defense Force (JMSDF)—which
consists of about 850,000 sets of examination data
accumulated over the past ten years—was surveyed, and
21,260 persons were selected that had serum urate data
available for screening of renal hypouricemia (the ﬂow
chart is shown in Figure 1). All procedures were carried
out in accordance with the standards of the institutional
ethical committees involved in this project and the exper-
iments were performed according to the Declaration of
Helsinki. After written consent had been given by each
participant, blood samples were obtained. Among those,
there were 200 persons (0.94%) who showed serum urate
levels %3.0 mg/dl (178 mM) (Table 1). To date, we have
written consent from 50 JMSDF persons and 20 outpa-
tients with hypouricemia, and clinicogenetic analysis was
performed on these 70 hypouricemic cases. We excluded
cases with the most-frequent mutation (W258X) in the
URAT1 gene, which left 23 hypouricemic cases without
the URAT1 W258X mutation, on which we performed ge-
netic analysis of the GLUT9 gene. The human GLUT9 gene
contains 14 exons and produces two main transcripts:
GLUT9 isoform 1 (long isoform, GLUT9L, also known as
GLUT911) and isoform 2 (short isoform, GLUT9S, also
known as GLUT9DN11) (Figure 2). We performed muta-
tional analysis of all coding regions and intron-exon
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Figure 1. The Flowchart for Clinicogenetic Analysis of Hypouricemia with GLUT9 Mutations
(a) We surveyed the health examination database of about 50,000 personnel of Japan Maritime Self-Defense Force (JMSDF). The database
contains data for about 850,000 sets of examinations over 10 years (Apr. 1, 1997 to Mar. 31, 2007). To screen for renal hypouricemia, we
selected 21,260 personnel data sets from 2006 in which serum urate data were available (b). (c) The number of persons who showed serum
urate levels% 3.0 mg/dl (178 mM) was 200 (0.94%) out of 21,260 persons. (d) 50 JMSDF persons who gave written consent and (e) an
additional 20 outpatients with hypouricemia ([f] 70 hypouricemic cases in sum) participated in this clinicogenetic study. (g) First, we
performed mutational analysis of URAT1 exon 4, to detect the most frequent mutation (W258X) in URAT1. (h) After 47 cases having the
URAT1 W258X mutation were excluded, (i) remaining 23 hypouricemic cases were analyzed to find mutations in GLUT9. (j) After exclusion
of known frequent SNPs or high-frequency mutations in Japanese controls, (k) 2 missense mutations (R380W and R198C) in GLUT9 were
selected. (l) Subsequently, the patients with these GLUT9 mutations were confirmed to have no URAT1 mutations by whole-sequence
analysis of URAT1. (m) Urate uptake activity was measured using oocytes, and these two mutations were proved to be loss-of-function
mutations. (n) Further clinical investigations including a hypoxanthine assay and fractional excretion of urate (FEUA) were performed to
confirm that the cases are true renal hypouricemia. (o) A pyrazinamide loading test and further familial studies were performed in possible
cases. (p) Finally, two loss-of-function mutations in GLUT9 were identified as a cause of renal hypouricemia.GLUT9 sequence, we used primers described by Li et al.8
with slight modiﬁcations (Table S1 available online).
Some primers were newly selected according to the geno-
mic structure of human GLUT9 (see Figure 2). For determi-
nation of the URAT1 sequence, primers as described
elsewhere3,5 were used. High-molecular-weight genomic
DNA was extracted from whole peripheral blood cells12,13
as a template and was ampliﬁed by PCR. The PCR products
were sequenced in both directions13 with a 3130xl Genetic
Analyzer (Applied Biosystems). Through this analysis, we











0.0–0.5 3 3 0.01 0.01
0.6–1.0 27 30 0.13 0.14
1.1–1.5 2 32 0.01 0.15
1.6–2.0 7 39 0.03 0.18
2.1–2.5 29 68 0.14 0.32
2.6–3.0 132 200 0.62 0.94
3.1– 21060 21260 99.06 100.00The Americanidentiﬁed two distinct heterozygous missense mutations
(R380W and R198C in GLUT9L, corresponding to
R351W and R169C in GLUT9S) in three patients with hy-
pouricemia (Figures 3A–3C). By digesting the PCR products
with restriction enzyme BtsCI (Table S1), the cosegregation
of the R380W substitution genotype with the low-urate
phenotype was conﬁrmed, being seen in both an affected
mother (serum urate: 1.5 mg/dl, 70 years old, I-2) and her
affected son (serum urate: 2.7 mg/dl, 43 years old, II-1), but
not in unaffected members of the same family (Figure 3D).
The fractional excretion of urate was 15.7% in I-2 and
14.6% in II-1, respectively. A pyrazinamide loading test1,5
of the patient II-1 revealed a normal response, indicating
that there is no functional alternation in URAT1. The
R198C substitution (Figure 3E) was observed in a hypouri-
cemic 32-year-old female patient whose serum urate level
was 2.1 mg/dl. Whole-sequence analysis of the URAT1
gene was performed in patients having GLUT9 mutations
(R380W or R198C), and it was conﬁrmed that they have
no mutations in the URAT1 gene. Together with other
clinical data, they were diagnosed as renal hypouricemia
without URAT1mutation (Figure 1). For the genotyping of
Japanese controls and family members, the mutations ofJournal of Human Genetics 83, 744–751, December 12, 2008 745
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Figure 2. Genomic Structure of the Human GLUT9 Gene
(A) The structure of the GLUT9 gene and cDNAs. The human GLUT9 gene contains 14 exons (1 noncoding and 13 coding) and is located on
chromosome 4p15.3-p16. The alternative splicing of the GLUT9 gene results in two main transcripts: GLUT9 isoform 1 (long isoform,
GLUT9L) and isoform 2 (short isoform, GLUT9S).
(B) Exon-intron boundaries of the GLUT9 gene.GLUT9 in exon 10 (R380W) and in exon 6 (R198C) were
detected by restriction digestion of the PCR product with
BtsCI and AlwI, respectively (Table S1). Neither R380W
nor R198C mutations were detected in any samples from
130 randomly selected Japanese controls (260 total chro-
mosomes). For prediction of human GLUT9 membrane
topology model, the transmembrane regions of GLUT9L
and GLUT9S were predicted based on the TMpred algo-
rithm. N-glycosylation sites and phosphorylation sites
were predicted by PROSITE (Figure 3A).
To investigate the functional aspect of these mutations,
either wild-type or mutated GLUT9 cRNA was injected
into Xenopus oocytes and the urate transport activity was
measured. Complementary DNAs (cDNAs) of human
GLUT9L (long isoform) and GLUT9S (short isoform) were
obtained from Open Biosystems (also see Accession Num-
bers section). The GLUT9L cDNA insert was subcloned into
pcDNA3.1(þ) (Invitrogen) at the KpnI and NotI restriction
enzyme cleavage sites. The GLUT9S cDNA insert was subcl-
oned into pcDNA3.1(þ) at the EcoRI and XhoI restriction
enzyme sites. Site-directed mutagenesis of GLUT9L and
GLUT9S cDNAs in the pcDNA3.1(þ) plasmid was carried
out with the QuickChange kit (Stratagene).14 Oligonucleo-
tide primers for the generation of R380W mutant in746 The American Journal of Human Genetics 83, 744–751, DecembGLUT9L or R351W mutant in GLUT9S were 50-GGTCA
TTGAGCACCTGGGA(T)GGAGACCCCTCCTCATTGG-30
and 50-CCAATGAGGAGGGGTCTCC(A)TCCCAGGTGCT
CAATGACC-30. The mutagenic primers for the generation
of R198C (GLUT9L) or R169C (GLUT9S) mutants were 50-C
ACCCAAGGAGATC(T)GTGGCTCTCTGGGGC-30 and 50-G
CCCCAGAGAGCCAC(A)GATCTCCTTGGGTG-30. The ac-
curacy of the mutated cDNAs was conﬁrmed by complete
sequencing of the constructs with the dye terminator cycle
sequence method (Applied Biosystems). For the evaluation
of urate uptake activity, Xenopus laevis oocytes were in-
jected with 25 ng of cRNA that was synthesized in vitro
from linearized GLUT9L or GLUT9S cDNAs. In vitro
transcription of the cRNA was performed with the T7
mMESSAGE mMACHINE Kit (Ambion). The urate trans-
port activity was measured 2 days after cRNA injection.7,15
The uptake of 14C-labeled urate (1.25 mCi ml1) by the oo-
cytes was measured in the regular uptake solution (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM
HEPES [pH 7.4]) containing 0.9 mM of urate for 1 hr. The
uptake activity was measured in triplicate and expressed
as pmol per oocyte per min. The oocytes expressing wild-
type GLUT9L showed a 44-fold uptake of 14C-labeled urate
relative to water-injected control oocytes. In the oocyteser 12, 2008
injected with mutant GLUT9L (R380W or R198C) cRNA,
urate transport was dramatically suppressed (Figure 4A).
The oocytes expressing wild-type GLUT9S also showed
highurate uptake relative towater-injected control oocytes,
whereas the oocytes injectedwithmutantGLUT9S (R351W
or R169C) cRNA showed markedly suppressed urate trans-
port (Figure 4B). These results were consistent with those
from mutant URAT14,5 that cause renal hypouricemia.
These results indicate the malfunction of both mutated
GLUT9 isoforms (GLUT9L and GLUT9S) in the pathophys-
iological condition. The expression ofwild-type ormutated
GLUT9 proteins on the plasma membrane was conﬁrmed
by immunoﬂuorescence staining with anti-GLUT9 (Fig-
ure S1). Immunoﬂuorescent detection of GLUT9 protein




Figure 3. GLUT9 Mutations in Patients
with Renal Hypouricemia
(A) Mutation positions in a predicted
human GLUT9 membrane topology model.
Both mutations are present at equivalent
positions within the cytoplasmic loops,
which result in loss of positive charges.
(B and C) Heterozygous mutations
(c.1138C/ T [p.R380W] and c.592C /
T [p.R198C]; indicated by magenta arrows)
were identified in the patients with renal
hypouricemia.
(D) The R380W mutation results in the
gain of a BtsCI restriction site. A family
tree of the hypouricemic patients having
the R380W mutations is shown with serum
urate levels.
(E) The R198C mutation results in the loss
of an AlwI site.
described previously,16,17 with minor
modiﬁcations. In brief, 2 days after in-
jection of cRNAs, Xenopus oocytes
were ﬁxedwith 4%paraformaldehyde
in phosphate buffer at 4C overnight.
The sections (4 mm) were incubated
with rabbit anti-human GLUT9
(Alpha Diagnostic Intl. Inc; diluted
1:500) for 2 hr at room temperature.
Thereafter, they were treated with
FITC-conjugated goat anti-rabbit IgG
(Immunotech; diluted 1:100). The im-
ages were acquired with a Nikon C1
laser scanning confocal microscope
(Nikon, Tokyo, Japan). An Argon laser
beam at 488 nm was used for the
excitation of FITC and visualization.
Here, by using the large human da-
tabase, we identiﬁed loss-of-function
mutations of GLUT9 in renal hypour-
icemic patients who have no URAT1
mutations. The ﬁndings ﬁrst show
the genetic heterogeneity of renal hypouricemia. To collect
enough cases of hypouricemia for the analysis of patho-
genic GLUT9 mutations, the serum urate data from the
health examination database of the JMSDF were investi-
gated. Although there have been few reports on the fre-
quency of hypouricemia among large healthy populations,
we could demonstrate the frequency of individuals with
lower urate levels as shown in Table 1. The use of an actual
human health examination database enabled us to analyze
larger populations than those of the recent genome-wide
association studies,6–8 which have usually analyzed popu-
lations of less than 5000 having known SNPs. The use of
this large JMSDF human database in this study was essen-
tial in identifying pathogenic mutations in the GLUT9
gene. We believe that the large-database approach usedThe American Journal of Human Genetics 83, 744–751, December 12, 2008 747
in this study is a reliable and powerful way to identify
novel causative genes in such studies.
The sites of mutation identiﬁed in this study (R380W
and R198C) are both perfectly conserved in GLUT9 verte-
brate orthologs (Figure S2). They are also highly conserved
in the GLUT family transporters (Figure 5). Interestingly,
GLUT1 deﬁciency syndrome (MIM 606777) is caused by
heterozygous mutations in human GLUT1 (R333W and
R153C),18 which correspond to the mutation sites in hu-
man GLUT9 (R380W and R198C, respectively). Moreover,
both the GLUT9 and GLUT1 mutations occur in ‘‘sugar
transport proteins signatures 1 and 2,’’ which are highly
conserved in most sugar transport proteins among yeast,
bacteria, plants, and mammals (Figure S3). One of the
sugar transport proteins signatures contains a well-known
conserved amino acid motif (D/E-x(2)-G-R-R)19 (Figure 5),
and pathogenic mutations in GLUT9 (R380W) and GLUT1
(R333W) are identiﬁed in this motif. Sato and Mueckler
showed that positive charge (arginine residues) in this
conserved motif plays a critical role in forming cytoplas-
mic anchor points that are involved in determining the
membrane topology of GLUT1.20 The loss of these positive
charges in GLUT1 completely abolished transport activi-
ties as a result of a local perturbation in the membrane
topology, resulting in aberrant ‘‘ﬂipping’’ of the corre-
sponding cytoplasmic loop into the exogenous compart-
ment.20 They suggested that this ﬁnding provides a simple
Figure 4. Markedly Reduced Urate Transport Activities in
Oocytes that Express Mutant GLUT9 Isoforms
High urate transport activities were observed in oocytes that
express each wild-type GLUT9 isoform. In contrast, urate transport
activity in oocytes was markedly reduced both in GLUT9L mutants
(R380W and R198C) (A) and in GLUT9S mutants (R351W and R169C,
which correspond to R380W and R198C in GLUT9L) (B). Results are
expressed as mean 5 SEM.748 The American Journal of Human Genetics 83, 744–751, Decembexplanation for the presence of this conserved motif in
hundreds of membrane transporters that share a common
predicted membrane topology.20 The marked reduction of
the urate transport activity in mutated GLUT9 may be as-
cribed to the loss of a cytoplasmic anchor point and the
perturbation of the membrane topology. Arginine residues
in GLUT4, which correspond to R380 and R198 in GLUT9,
have also been shown to be essential for its appropriate
comformation.21
To test whether heterozygous GLUT9 mutations cause
hypouricemia because of dominant-negative effects, we
performed additional functional studies with oocytes coin-
jected with wild-type andmutant GLUT9 cRNA. Coexpres-
sion of wild-type and mutant GLUT9 did not reduce the
urate transport (Figure S4), which suggests that GLUT9
mutants may not induce dominant-negative effects.
GLUT1 deﬁciency syndrome is caused by GLUT1 heterozy-
gous mutations because of haploinsufﬁciency,22,23 which
was conﬁrmed by the uptake studies with patient-derived
cells such as erythrocytes. In the case of GLUT9, however,
there are no available patient-derived cells that are known
to show sufﬁcient GLUT9 functions. GLUT9 mutations
may also cause hypouricemia because of haploinsufﬁ-
ciency rather than dominant-negative effects, which
should be conﬁrmed by further experiments.
Because humans lack uricase, there are considerable
differences in urate metabolism between humans and
mice.10 Furthermore, the expression of GLUT9 in human
kidney is quite different from that inmouse kidney.Human
GLUT9 is expressed in the proximal tubules,11 whereas
mouse GLUT9 is expressed in the distal convoluted tubules
or connecting tubules of the renal cortex.24 Moreover, the
isoforms of mouse GLUT9 (GLUT9a and GLUT9b) show
only basolateral localization in polarized MDCK cells,24
whereas the isoforms of humanGLUT9 show a different ex-
pressionpattern; i.e., humanGLUT9L (long isoform) shows
basolateral localizationandhumanGLUT9S (short isoform)
shows apical localization inMDCK cells.11 Because of these
considerable differences, the investigation of human pa-
tients with loss-of-function GLUT9 mutations has a great
advantage for the analysis of the urate transporting activity
by GLUT9 relative to using GLUT9 gene-targeted mice.
As mentioned above, the human GLUT9 protein is
supposed to be expressed on both sides of renal proximal
tubules, which should be conﬁrmed by the further immu-
nohistochemical analysis with speciﬁc antibodies against
human GLUT9 isoforms. In contrast, the human URAT1
protein expresses only on the apical side. Together with
this renal localization, our data of reduced function in
both mutant GLUT9 isoforms indicate that impaired urate
reabsorption occurs on both sides of the proximal tubules
in patients with these mutations (Figure 6). Based on our
ﬁndings and previous reports on renal localization of
GLUT9, we propose a physiological model of renal urate
transport, in which two isoforms of GLUT9 play a key
role in urate reabsorption on both urine and blood sides
of the renal proximal tubules (Figure 6). Because thereer 12, 2008
Figure 5. Amino Acid Conservation in the GLUT Family Transporters
Arginine residues homologous to human GLUT9 amino acid positions 380 and 198, the sites of missense mutations identified in hypo-
uricemia patients, are boxed in magenta. These mutations are observed at the well-known conserved motif (D/E-x(2)-G-R-R/K) and
another conserved motif (Y-x(2)-E-x(6)-R-G) that is 100% conserved in all GLUT family transporters. These motifs are a part of the
consensus patterns 1/2 that are demonstrated in the PROSITE database as ‘‘sugar transport proteins signatures 1/2’’ (also see
Figure S3). The mutation sites in GLUT9 are found to be key residues in these consensus patterns. Interestingly, mutations of human
GLUT1 at amino acid positions 333 and 153 (magenta), which correspond to the human GLUT9 mutation sites, are reported to cause
GLUT1 deficiency syndrome. hHMIT represents human Hþ-coupled myo-inositol transporter, also known as SLC2A13.had been no clear in vivo evidence of the molecules that
mediate urate reabsorption on the basolateral side, our
ﬁndings provide the ﬁrst evidence for the these molecules
on the basolateral side (Figure 6). The presence of SNPs as-
sociated with gout found in recent studies6–9 implies that
these SNPs relate to increased function of GLUT9 (renal ur-
ate reabsorption), but no functional evidence is shown.
Increased renal urate reabsorption would result from
increased protein expression of GLUT9, which should be
proved by further experiments.
Our results conﬁrmed the ability of both GLUT9L and
GLUT9S to transport urate and showed the existence of
loss-of-function mutations of GLUT9 in hypouricemic
patients via the oocyte expression system. The ability of
GLUT9 to transport glucose was also reported via a high-
sensitivity intramolecular FRET glucose sensor,25 suggest-
ing multifunctional aspects of this transporter. Although
urate did not inhibit D-glucose or D-fructose uptake via an
oocyte expression system, Cauﬁeld et al. suggested that
GLUT9 can exchange extracellular glucose for intracellular
urate.26 Further investigationof the functional properties of
GLUT9 will be helpful in elucidating the other physiologi-
cal and pathophysiological roles of this transporter.
Very recently, functional properties of GLUT9 have been
reported,27 which support the biological signiﬁcance of
our ﬁndings on GLUT9 pathogenic mutations. Also re-
ported was a case of hypouricemia with a GLUT9 aminoThe Americanacid alternation (P412R)27 that had less effect on the trans-
port function. Our data suggest that P412R is unlikely to be
a pathogenic mutation for renal hypouricemia, because it
does not reduce the function (Figure S5). Taken together,
we have identiﬁed GLUT9 as a causative gene for renal hy-
pouricemia and demonstrated that human GLUT9 physio-
logically regulates serum urate levels in vivo. Our results
also indicate that GLUT9 can be a promising therapeutic
target for hyperuricemia, gout, and related cardiovascular
diseases.
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The amino acid sequences of GLUT9L and GLUT9S shown in Fig-
ure 3A were obtained from GenBank (accession codes BC110414
A
B
Figure 6. Proposed Model of Renal Urate Reabsorption
in Humans
(A) Based on the findings from the hypouricemic patients
with pathogenic GLUT9 mutations, we propose a physiolog-
ical model of renal urate transport via human GLUT9 mole-
cules. The localization of GLUT9L and GLUT9S is based on
the previous observation from polarized MDCK cells. Here,
GLUT9 mediates renal urate reabsorption on both sides of
proximal tubular cells. URAT1 is expressed only on the
apical side and is indirectly coupled with Naþ-anion co-
transporters, such as monocarboxylic acid transporter1/2
(MCT1/2).
(B) An impaired urate reabsorption model in the renal prox-
imal tubular cells. Pathogenic mutations in GLUT9L and
GLUT9S on both sides of proximal tubules markedly reduce
the urate reabsorption and cause hypouricemia. GLUT9L or
‘‘GLUT9’’ represents GLUT9 isoform 1 (long isoform) and the
GLUT9S or GLUT9DN represents GLUT9 isoform 2 (short iso-
form). PZA represents pyrazinecarboxylic acid, a metabolite
of pyrazinamide that is used for loading test of
hypouricemic patients.
and BC018897, respectively). Their sequences are identical
to those from the GLUT9 clones used in this study.
PROSITE accession codes for consensus patterns shown
in Figure 5 are PS00216 (Sugar transport proteins signature
1) and PS00217 (Sugar transport proteins signature 2).
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Note Added in Proof
In the version of Table 1 published online ahead of the print issue,
the ﬁnal entry in the ﬁrst column, ‘‘Frequency,’’ was incorrectly
edited. The correct entry is 21060. The corrected version of the ta-
ble appears in this ﬁnal version of the manuscript.n Journal of Human Genetics 83, 744–751, December 12, 2008 751
